Opus Point Partners Management Lowers stake in Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX) : Opus Point Partners Management reduced its stake in Vertex Pharmaceuticals Incorporated by 1.26% during the most recent quarter end. The investment management company now holds a total of 41,137 shares of Vertex Pharmaceuticals Incorporated which is valued at $4,176,640 after selling 525 shares in Vertex Pharmaceuticals Incorporated , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Vertex Pharmaceuticals Incorporated makes up approximately 3.49% of Opus Point Partners Management’s portfolio.

Other Hedge Funds, Including , Brown Brothers Harriman Co sold out all of its stake in VRTX during the most recent quarter. The investment firm sold 115 shares of VRTX which is valued $11,676.Hsbc Holdings Plc reduced its stake in VRTX by selling 20,448 shares or 16.39% in the most recent quarter. The Hedge Fund company now holds 104,320 shares of VRTX which is valued at $10,591,610. Vertex Pharmaceuticals Incorporated makes up approx 0.03% of Hsbc Holdings Plc’s portfolio.Scotia Capital boosted its stake in VRTX in the latest quarter, The investment management firm added 290 additional shares and now holds a total of 9,831 shares of Vertex Pharmaceuticals Incorporated which is valued at $998,141. Vertex Pharmaceuticals Incorporated makes up approx 0.02% of Scotia Capital’s portfolio.Edmond De Rothschild Asset Management (france) boosted its stake in VRTX in the latest quarter, The investment management firm added 11,700 additional shares and now holds a total of 200,000 shares of Vertex Pharmaceuticals Incorporated which is valued at $20,306,000. Vertex Pharmaceuticals Incorporated makes up approx 0.92% of Edmond De Rothschild Asset Management (france)’s portfolio.Royal London Asset Management Ltd reduced its stake in VRTX by selling 4,630 shares or 5.32% in the most recent quarter. The Hedge Fund company now holds 82,359 shares of VRTX which is valued at $8,272,138. Vertex Pharmaceuticals Incorporated makes up approx 0.13% of Royal London Asset Management Ltd’s portfolio.

Vertex Pharmaceuticals Incorporated opened for trading at $95.03 and hit $95.88 on the upside on Thursday, eventually ending the session at $94.75, with a gain of 0.25% or 0.24 points. The heightened volatility saw the trading volume jump to 9,66,637 shares. Company has a market cap of $23,477 M.

On the company’s financial health, Vertex Pharmaceuticals Incorporated reported $0.24 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.20. The company had revenue of $431.61 million for the quarter, compared to analysts expectations of $429.58 million. The company’s revenue was up 159.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.54 EPS.

Many Wall Street Analysts have commented on Vertex Pharmaceuticals Incorporated. Shares were Reiterated by Stifel on Aug 16, 2016 to “Buy” and Lowered the Price Target to $ 105 from a previous price target of $108 .

Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertex’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs including programs in the areas of oncology and neurology. The Company’s product candidates include KALYDECO (ivacaftor) Lumacaftor in combination with Ivacaftor VX-661 in combination with Ivacaftor VX-803 VX-970 and VX-222. The Company’s product KALYDECO is available in the market.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *